
New KRAS-Targeted Therapy Shows Early Promise for Lung and Pancreatic Cancer
Quick Summary A new investigational targeted therapy (setidegrasib) targets the KRAS G12D mutation, common in pancreatic cancer and some lung cancers. In a phase 1 clinical trial of 203 patients, objective response rate was 36% for non-small cell lung cancer and 24% for pancreatic cancer. The drug helps cancer cells











